Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantRI
RTW Investments
Activity from announced rounds
All recorded activity
RTW Investments is the investment manager named in Amani and Encoded financing histories.
Recorded funding activity
Amani develops combination medicines for neuropsychiatric disorders. Encoded develops gene-regulation therapies for neurological disease. The histories refer to the manager rather than a specified RTW fund.
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $900M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in all activityAmani Therapeutics
Biotechnology company developing combination medicines for serious neuropsychiatric disorders.
$25MSeries A
Role not disclosedCorxel Pharmaceuticals
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
≤$287MSeries D1
ParticipantKailera Therapeutics
Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms.
$600MSeries B
Participant